Mirum Pharmaceuticals (MIRM) PT Lowered to $137 at Citizens
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Price: $83.27 +3.58%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 56
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 56
Join SI Premium – FREE
Citizens analyst Jonathan Wolleben lowered the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $137.00 (from $146.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Mirum's zilurgisertib shows positive results in younger FOP patients
- Northrop Grumman (NOC) PT Raised to $590 at Bernstein SocGen Group
- Clearwater Paper (CLW) PT Lowered to $17 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
